Trial · NCT07569536
Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock
NCT07569536, Phase 3, Not yet recruiting, Hospices Civils de Lyon
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock. Trials, record NCT07569536. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07569536
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock
- NCT number
- NCT07569536
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 360 participants, estimated
- Lead sponsor
- Hospices Civils de Lyon
- Conditions
- Septic Shock, Vasopressor Resistance
- Interventions
- Dexmedetomidine 100 µg/mL, intravenous solution, Stardard care
- First posted
- 2026-05-06
- Last updated
- 2026-05-06
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 30-day mortality | Day 30 after randomization | Vital status at day 30 after randomization. |
| Secondary | 72-hour mortality | 72 hours after randomization | Vital status at 72 hours after randomization |
| Secondary | Vasopressor exposure | 6, 12 and 24 hours after randomization | Cumulative vasopressor dose and peak vasopressor dose expressed as norepinephrine-equivalent dose (NEE score) |
| Secondary | Use of vasopressin or recue therapies | From randomization to day 30 | Proportion of patients requiring vasopressin or any therapy for refractory shock during follow-up |
| Secondary | Mean arterial pressure (MAP) | Baseline, 6 hours, 12 hours and 24 hours after randomization | Evolution of mean arterial pressure (MAP) and MAP to norepinephrine-equivalent (Neq) dose ration (MAP/Neq) to assess vasopressor responsiveness |
| Secondary | Vasopressor-free days | Day 0 to day 30 | Number of days without vasopressor therapy during the first 30 days following randomization |
| Secondary | Mechanical ventilation-free days | Day 0 to day 30 | Number of days without mechanical ventilation during the first 30 days following randomization |
| Secondary | Blood lactate concentration | 6 hours, 12 hours and 24 hours after randomization | Arterial blood lactate levels |
| Secondary | SOFA score | Baseline and day 3 after randomization | Evolution of organ failure assessed using the Sequential Organ Failure Assessment (SOFA) score (minimum 0, maximum 24). |
| Secondary | Cumulative fluid balance | Day 0 to day 5 | Difference between total fluid intake and total fluid output |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07569536
GET https://conductscience.org/api/trials/v1/NCT07569536/registered